Patents by Inventor Renate Konopitzky

Renate Konopitzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Tri-specific Binding Molecules
    Publication number: 20220411533
    Abstract: The present invention relates to novel tri-specific binding molecules. The invention also relates to nucleic acids encoding such binding molecules; to methods for preparing such binding molecules; to host cells expressing or capable of expressing such binding molecules; to compositions comprising such binding molecules; and to uses of such binding molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 29, 2022
    Inventors: Paul ADAM, Stephen R. COMEAU, Philip Nicholas GORMAN, Pankaj Gupta, Priyanka GUPTA, Karl-Heinz HEIDER, Srinath KASTURIRANGAN, Renate KONOPITZKY, Klaus-Peter KUENKELE, Sandeep KUMAR, Taneisha Ann-Tanara MACK, Elinborg Katrin OSTERMANN, Abdulsalam SHAABAN, David WEISMANN, Andreas WERNITZNIG, David S. YOUNG
  • CD33 BINDING AGENTS
    Publication number: 20190256593
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: December 17, 2018
    Publication date: August 22, 2019
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • CD33 binding agents
    Patent number: 10202451
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • CD33 BINDING AGENTS
    Publication number: 20170088617
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • CD33 binding agents
    Patent number: 9550833
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: January 24, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • CD33 BINDING AGENTS
    Publication number: 20150284462
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: June 18, 2015
    Publication date: October 8, 2015
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • CD33 binding agents
    Patent number: 9079958
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Eric Borges, Paul Adam, Karl-Heinz Heider
  • CD33 BINDING AGENTS
    Publication number: 20120082670
    Abstract: The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).
    Type: Application
    Filed: September 27, 2011
    Publication date: April 5, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Renate KONOPITZKY, Eric BORGES, Paul ADAM, Karl-Heinz HEIDER
  • Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)
    Patent number: 7745585
    Abstract: The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: June 29, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Zophel, Horst Johann Ahorn, Birgit Jung, Renate Konopitzky, Karl-Heinz Heider, Norbert Kraut, Peter Seither, Thomas Waerner, Hartmut Beug, Martin Jechlinger, Ido M. Tamir, Andreas Weith, Stefan Gruenert
  • Cytokine involved in epithelial-mesenchymal transition
    Publication number: 20070089176
    Abstract: The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
    Type: Application
    Filed: September 2, 2004
    Publication date: April 19, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Andreas Zoephel, Horst Ahorn, Birgit Jung, Renate Konopitzky, Karl-Heinz Heider, Norbert Kraut, Peter Seither, Thomas Waerner, Hartmut Beug, Martin Jechlinger, Ido Tamir, Andreas Weith, Stefan Gruenert
  • Tumor-associated antigen (R11)
    Patent number: 6809179
    Abstract: Tumor-associated antigens, immunogenic peptides derived therefrom and DNA molecules coding therefor, and the use thereof in the immunotherapy of cancers.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: October 26, 2004
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Renate Konopitzky, Ulrich Koenig, Wolfgang Sommergruber, Thomas Woelfel